The FDA says promotional materials for Anktiva gave a misleading picture of what the bladder cancer drug can treat and how it is used. Here is what the drug is actually approved for, who it may fit, how it is given, and why the study behind the approval matters.
The FDA has approved the first generic of Flovent HFA, but this is not a simple fix for every family affected by the brand-name inhaler’s discontinuation. Here’s what changed, who it may help, and why coverage and pharmacy access may still be uneven.
CMS has started a limited Original Medicare pilot in six states that uses technology vendors and clinician review for a narrow set of services. Here’s what WISeR does, what has not changed, how reviews and appeals work, and why some experts worry about delays.
If your clinician says an AI tool will listen to the visit and draft the note, the newest U.S. evidence suggests modest paperwork savings for clinicians, not a proven transformation of care. Here is what these tools do, what remains uncertain, and what patients should ask about privacy, accuracy, and opt-out choices.
As of April 2, 2026, nothing changes at the pharmacy yet for Medicare patients taking Xeljanz, Orencia, Cosentyx, or Cimzia. What changed is that Medicare has selected these drugs for its third negotiation cycle, manufacturers are participating, and any negotiated prices would not begin until January 1, 2028.
CDC’s new nursing-home respiratory virus toolkit gives families a practical way to ask better questions. If you are choosing, visiting, or monitoring a nursing home, here are the five things to ask about vaccines, testing, treatment, outbreak response, and communication.
A November 6, 2025 study found that hearing loss was common among Hispanic Medicare beneficiaries age 65 and older, but hearing aid use was much lower. Here is what the study found, what Original Medicare does and does not cover, where OTC hearing aids may fit, and when it is time to get tested.
CMS has announced first-year awards in all 50 states under a five-year rural health program. The funding could help states recruit, train, and keep more clinicians, but federal workforce data show rural primary care shortages remain deep and patient-facing relief is likely to take time.
Federal enforcement of updated hospital price transparency requirements begins April 1, 2026. That may make some hospital price listings more useful for planned care, but posted prices still are not the same as your final out-of-pocket bill.
ACA Marketplace sign-ups for 2026 came in below last year, and many households are paying more after tax credits. Here is what changed, who may still qualify to enroll, and what to do if your plan or subsidy looks wrong.
Certain Medicare Advantage, Medicaid, CHIP, and HealthCare.gov marketplace plans now have to post prior authorization data from 2025. Here’s what patients can check, what the numbers mean, and what the reports still leave out.
Most people with 2 documented MMR doses do not need another measles shot. Here’s who should check records now, especially travelers, parents, students, and healthcare workers.
If you get Marketplace premium help in 2026, the financial stakes are higher than they were before. Extra pandemic-era subsidy boosts have ended, and for tax years after 2025 there is no repayment cap if you get too much advance premium tax credit. Here’s what that means, who should act now, and where to get help.
CMS is asking states to break out more Medicaid and CHIP quality results by race and ethnicity, sex, and geography in 2026. That could make gaps in child, pregnancy, and behavioral health care easier to see, but better reporting alone will not fix unequal care.
Many ACA Marketplace enrollees are paying more in 2026 after enhanced subsidies ended. If you already signed up, now is the time to verify premium payments, update your income information, and understand the risk of retroactive coverage loss or a tax-time payback.
Measles cases and outbreaks are up in the United States in 2026. Here’s how to recognize early symptoms, what to do after an exposure, and how to check whether you or your child are protected by MMR.
New CDC data show the 2025-26 flu shot was a weaker match against drifted viruses, but it still lowered the odds of doctor visits and hospitalization. Here’s what happened, who should seek treatment quickly, and what is changing for next season.
A newly published New England Journal of Medicine trial adds stronger evidence behind Ajovy for some children and teens with episodic migraine. The study found modest average benefit, not a cure, and the current U.S. label applies only to patients ages 6 to 17 who weigh 45 kg or more.
A new measles alert for the Americas matters in the United States because travel-related cases can still spark local outbreaks. Here’s what families, travelers, and higher-risk groups should know now about MMR protection, symptoms, and what to do after possible exposure.
CMS now requires hospitals to report clearer dollar-based pricing fields in their machine-readable files for 2026. That could make gathered pricing data easier to analyze, but it still does not give most patients an exact out-of-pocket quote.
A new federal outbreak warning tied to raw cheddar cheese is a reminder that not every food safety alert comes with a recall. Here’s what changed, who may be at higher risk, symptoms to watch for, and what to do if the product is in your home.
No, 10,000 steps a day is not an official U.S. fitness rule. Federal guidance still focuses on weekly activity minutes plus strength training, while newer studies suggest meaningful health benefits can begin below 10,000 steps for many adults.
End of content
End of content
